{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:06:08Z","timestamp":1786118768564,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1097\/qad.0b013e3280f00f9f","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T04:04:13Z","timestamp":1180670653000},"page":"1293-1299","source":"Crossref","is-referenced-by-count":72,"title":["Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults"],"prefix":"10.1097","volume":"21","author":[{"given":"Dirk","family":"Sch\u00fcrmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"F\u00e4tkenheuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Reynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Michelet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Raffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"van Lier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Caceres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anther","family":"Keung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Sansone-Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M","family":"Dunkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210130","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/312763a0","article-title":"The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus","volume":"312","author":"Dalgleish","year":"1984","journal-title":"Nature"},{"key":"R2-8-20210130","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1126\/science.272.5263.872","article-title":"HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor","volume":"272","author":"Feng","year":"1996","journal-title":"Science"},{"key":"R3-8-20210130","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/384179a0","article-title":"CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5","volume":"384","author":"Wu","year":"1996","journal-title":"Nature"},{"key":"R4-8-20210130","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1084\/jem.174.2.407","article-title":"Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding","volume":"174","author":"Sattentau","year":"1991","journal-title":"J Exp Med"},{"key":"R5-8-20210130","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1073\/pnas.97.1.343","article-title":"The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions","volume":"97","author":"Murakami","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R6-8-20210130","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1089\/aid.1993.9.1051","article-title":"A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion","volume":"9","author":"Wild","year":"1993","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R7-8-20210130","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/3293","article-title":"Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry","volume":"4","author":"Kilby","year":"1998","journal-title":"Nat Med"},{"key":"R8-8-20210130","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1021\/jm0304515","article-title":"Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperaz inyl]-4-methylpiperidine (Sch-417690\/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist","volume":"47","author":"Tagat","year":"2004","journal-title":"J Med Chem"},{"key":"R9-8-20210130","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1021\/jm015526o","article-title":"Discovery of 4-[(Z)-(4-bromophenyl)-(ethoxyimino)methyl]-1\u2032-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4\u2032-methyl-1,4\u2032-bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection","volume":"44","author":"Palani","year":"2001","journal-title":"J Med Chem"},{"key":"R10-8-20210130","doi-asserted-by":"crossref","first-page":"12718","DOI":"10.1073\/pnas.221375398","article-title":"SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo","volume":"98","author":"Strizki","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R11-8-20210130","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1126\/science.273.5283.1856","article-title":"Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study","volume":"273","author":"Dean","year":"1996","journal-title":"Science"},{"key":"R12-8-20210130","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nm0496-412","article-title":"Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure","volume":"2","author":"Paxton","year":"1996","journal-title":"Nat Med"},{"key":"R13-8-20210130","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0092-8674(00)80110-5","article-title":"Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection","volume":"86","author":"Liu","year":"1996","journal-title":"Cell"},{"key":"R14-8-20210130","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1128\/AAC.49.12.4911-4919.2005","article-title":"Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1","volume":"49","author":"Strizki","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-8-20210130","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1056\/NEJM199512073332204","article-title":"A preliminary study of ritonavir, an inhibitor of the HIV-1 protease, to treat HIV-1 infection","volume":"333","author":"Markowitz","year":"1995","journal-title":"N Engl J Med"},{"key":"R17-8-20210130","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00126334-200301010-00004","article-title":"Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects","volume":"32","author":"Sanne","year":"2003","journal-title":"J Acquir Immun Defic Syndr"},{"key":"R18-8-20210130","doi-asserted-by":"crossref","first-page":"F197","DOI":"10.1097\/00002030-199816000-00001","article-title":"A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects","volume":"12","author":"Staszewski","year":"1998","journal-title":"AIDS"},{"key":"R19-8-20210130","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1086\/379667","article-title":"Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients","volume":"188","author":"Rousseau","year":"2003","journal-title":"J Infect Dis"},{"key":"R20-8-20210130","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/nm1319","article-title":"Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1","volume":"11","author":"Fatkenheuer","year":"2005","journal-title":"Nat Med"},{"key":"R21-8-20210130","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/01.aids.0000183633.06580.8a","article-title":"Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults","volume":"19","author":"Lalezari","year":"2005","journal-title":"AIDS"},{"issue":"Suppl. I","key":"R22-8-20210130","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1186\/1742-4690-2-S1-S12","article-title":"Vicriviroc is a novel, potent CCR5 inhibitor with outstanding pharmaceutic, pharmacokinetic and pharmacodynamic (PK\/PD) properties","volume":"2","author":"Dunkle","year":"2005","journal-title":"Retrovirology"},{"key":"R24-8-20210130","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1084\/jem.20051970","article-title":"CCR5 deficiency increases risk of symptomatic West Nile virus infection","volume":"203","author":"Glass","year":"2006","journal-title":"J Exp Med"},{"key":"R25-8-20210130","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1053\/gast.2002.33660","article-title":"Frequency of the HIV-protective CC chemokine receptor 5-\u039432\/\u039432 genotype is increased in hepatitis C","volume":"122","author":"Woitas","year":"2002","journal-title":"Gastroenterology"},{"key":"R26-8-20210130","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.296.7.815","article-title":"Biology of CCR5 and its role in HIV infection and treatment","volume":"296","author":"Lederman","year":"2006","journal-title":"JAMA"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002030-200706190-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:41:00Z","timestamp":1786034460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-200706190-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e3280f00f9f","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}